Monogram Technologies (Monogram Technologies) ROCE % : -118.75% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Monogram Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Monogram Technologies's annualized ROCE % for the quarter that ended in Mar. 2024 was -118.75%.

Monogram Technologies ROCE % Historical Data

The historical data trend for Monogram Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monogram Technologies ROCE % Chart

Monogram Technologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-367.17

-234.71

-250.71

-187.68

Monogram Technologies Quarterly Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial												-527.33	-330.34	-120.72	-119.15	-118.75

Monogram Technologies ROCE % Calculation

Monogram Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-17.268	/	( ( (13.69 - 9.049)	+	(16.579 - 2.818) )	/ 2 )
	=	-17.268	/	( (4.641	+	13.761)	/ 2 )
	=	-17.268	/	9.201
	=	-187.68 %

Monogram Technologies's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-14.44	/	( ( (16.579 - 2.818)	+	(12.542 - 1.984) )	/ 2 )
	=	-14.44	/	( ( 13.761	+	10.558 )	/ 2 )
	=	-14.44	/	12.1595
	=	-118.75 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Monogram Technologies (NAS:MGRM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Monogram Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Monogram Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Monogram Technologies (Monogram Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Monogram Technologies Inc (NAS:MGRM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

J7J:Germany

Address

3913 Todd Lane, Suite 307, Austin, TX, USA, 78744

Website

https://www.monogramorthopedics.com

Monogram Orthopaedics Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.

Executives

Paul H Riss	director
Noel Knape	officer: Chief Financial Officer	3913 TODD LANE, AUSTIN TX 78744
Benjamin Sexson	director, 10 percent owner, officer: Chief Executive Officer	3913 TODD LANE, AUSTIN TX 78744
Noel Goddard	director	3913 TODD LANE, AUSTIN TX 78744
Kamran Shamaei	officer: Chief Technology Officer	3913 TODD LANE, AUSTIN TX 78744
Douglas Unis	director	3913 TODD LANE, AUSTIN TX 78744